key: cord-0880191-mf45tflf
authors: Braghieri, Heloisa Amaral; Correia, Marília de Almeida; de Carvalho, Juliana Ferreira; Longano, Paulo; Wolosker, Nelson; Cucato, Gabriel Grizzo; Ritti-Dias, Raphael Mendes; Kanegusuku, Hélcio
title: Impact of the COVID-19 pandemic on drug treatment of patients with peripheral arterial disease: an observational cross-sectional study
date: 2021-06-17
journal: Jornal vascular brasileiro
DOI: 10.1590/1677-5449.210021
sha: 3fe5a6c4153214a5011d544be86ae29bc8a28495
doc_id: 880191
cord_uid: mf45tflf

BACKGROUND: The Coronavirus 2019 (COVID-19) pandemic has had a negative impact on the population’s behavior. In this context, the effect of the COVID-19 pandemic on drug treatment of patients with peripheral arterial disease (PAD) and intermittent claudication (IC) remains unclear. OBJECTIVES: To analyze the impact of the COVID-19 pandemic on drug treatment of patients with PAD and IC. METHODS: In this cross-sectional, observational study, 136 patients with PAD and IC were recruited from our database and answered a questionnaire by telephone involving the following questions: a) precautions related to COVID-19; b) general health status; and c) treatment of diseases. Subsequently, patients were divided into two groups according to difficulty in obtaining their drugs (DOD: difficulty obtaining drugs, or NDOD: no difficulty obtaining drugs) and overall health was compared between groups. RESULTS: Seventeen percent of patients reported difficulties with obtaining drugs during the pandemic. A higher proportion of these patients reported being sadder (56.5% vs. 24.8%, P < 0.01) and having more difficulty sleeping (56.5% vs. 24.8%, P < 0.01) than of the patients in the NDOD group (P <0.01). The groups did not differ in terms of impairment of walking capability, anxiety, stress, or depression (P> 0.05). CONCLUSIONS: A higher proportion of patients in the DOD group reported being sadder and having greater difficulty sleeping compared to the NDOD group during the COVID-19 pandemic.

Peripheral arterial disease (PAD) has higher prevalence among elderly people and is characterized by stenotic or obstructive lesions of the peripheral arteries that are normally due to atherosclerosis and which reduce or occlude the lumens of vessels and blood flow to the limbs, primarily the lower limbs. 1, 2 The most prominent risk factors are age, inactivity, diabetes mellitus (DM), systemic arterial hypertension (SAH), dyslipidemia, and smoking. 2 The reproducible symptoms of intermittent claudication (IC) seen in these patients, characterized by lower limb pain while walking, reduce their physical capability and, as a consequence, exacerbate their comorbidities and significantly reduce their quality of life. [3] [4] [5] [6] At the end of 2019, a new coronavirus (SARS-CoV-2) that causes a severe acute respiratory syndrome, named Coronavirus Disease 2019 (COVID- 19) , was identified for the first time in the city of Wuhan, China, and the subsequent COVID-19 epidemic was declared a global pandemic, with more than 99,363,690 cases and 2,135,950 deaths recorded worldwide by January 26, 2021. 7 One of the methods for minimizing dissemination of COVID-19, social isolation, has been adopted as an important strategy, particularly for high-risk groups, such as patients with PAD.

Some of the most prominent consequences of the pandemic for populations include increased inactivity and perceived deterioration of physical capability, health, and, as a consequence, quality of life. [8] [9] [10] [11] This clinical status can be even more severe for individuals who are exclusively dependent on the public health care system for treatment of diseases, including patients with PAD. These patients have faced difficulties obtaining their medications, since they generally have to collect them in person and need up-to-date medical prescriptions to do so. Social isolation has therefore amplified the treatment difficulties faced by these patients, many of whom were already finding it difficult to correctly adhere to treatment before the Covid-19 pandemic. 12 In this context, the objective of this study was to analyze the impact of the Covid-19 pandemic on drug treatment of patients with PAD and IC.

This was a cross-sectional, comparative, observational study of patients with PAD and IC. Information on the patients' characteristics was obtained from a study database maintained by the Cardiovascular Disease Clinical Interventions Research and Study Group (GEPICARDIO). Data relating to the impact of COVID-19 on patients were obtained by telephone interviews conducted from May 15 to August 22, 2020 , by health professionals with experience in studies with patients with PAD.

This study was approved by the Ethics Committee at the Universidade Nove de Julho (CAAE number 31529220.8.0000.5511; ruling number: 4.023.509). Participants' responses were included after they had given their consent. All procedures are in compliance with national Brazilian legislation and the Helsinki Declaration.

Patients were included if they met the following criteria: a) PAD diagnosis; b) age ≥ 45 years; c) previous ankle-brachial index ≤ 0.90; d) prior diagnosis of stage II disease according to the Fontaine classification; and e) absence of non-compressible vessels, limb amputations, and/or ulcers. Patients were only excluded if: a) they exhibited some type of deficiency during the phone call that could compromise administration of the questionnaire (e.g. cognitive, auditory, or speech disorders).

The personal information accessed from our database were sex ("woman" or "man"), date of birth (DD/MM/AAAA), time since PAD diagnosis (in years), body mass index (kg/m 2 ), and severity of PAD (ankle-brachial index and Fontaine stage). 3, 13 The questionnaire administered is of considerable length, but only the specific questions listed below were employed for the purposes of the present study:

Smoking: 1-Do you smoke?; 2-Are you an ex-smoker? The response choices for both items were: "No" or "Yes".

Comorbidities: the participants were read a list of diseases and asked whether they had been diagnosed with each one (diseases: DM, SAH, dyslipidemia, heart disease, respiratory disease, musculoskeletal diseases, or others). The response choices for all items were: "No" or "Yes":.

COVID-19: 1-Are you socially isolating?; 2-Have you been diagnosed with COVID-19?; If yes, 3-Have you recovered? The response choices for all items were: "No" or "Yes".

PAD Treatment: 1-Have you had difficulty obtaining your medications over the last few months because of COVID-19?; 2-Have you had to change the type/dosage of any of your medications?; 3-Are you responsible for collecting your own medications?; 4-How much do you spend per month on medications?; 5-Have you had to cancel an operation? The response options for items 1, 2, 3, and 5 were: "No" or "Yes". The response options for item 4, were: "Less than R$ 100.00", "R$ 101 to 200.00", "R$ 201 to 400.00" or "More than R$ 401.00".

Overall health: 1-How has your health been during the Covid-19 pandemic? (response options: "Good/unchanged" or "Poor"); 2-Have you had difficulty sleeping?; 3-Because of COVID-19, have you been feeling more anxious?; 4-Because of COVID-19, have you been feeling sadder?; 5-Because of COVID-19, have you been feeling more stressed? 6-Because of COVID-19, have you been feeling depressed?; 7-Have you felt that your ability to walk has reduced over the last few weeks? The response options for items 2 to 7 were: "No" or "Yes".

After the interviews, patients were allocated to one of two groups, depending on whether they had reported difficulty with obtaining their medications (DOD: difficulty obtaining drugs or NDOD: no difficulty obtaining drugs).

All analyses were conducted using the Statistical Package for the Social Sciences ® (SPSS, version 20). Comparisons between patients who did and did not encounter difficulty with obtaining their drugs were made using the independent t test or the Mann-Whitney U test and chi-square test. Data are expressed as means and standard deviations for continuous variables and relative frequencies for categorical variables. The level of significance was set at p < 0.05.

A flow diagram illustrating selection and classification of study participants is shown in Figure 1 . The 136 patients with PAD and IC who answered the questionnaire were divided into two groups according to whether they had had difficulty with obtaining their drugs (NDOD: 113 patients and DOD: 23 patients). The two groups had similar physical characteristics, risk factors, comorbidities, and percentages of group members practicing social isolation (p > 0.05) ( Table 1 ).

The groups also had similar results in terms of the percentages of patients responsible for collecting their own medications, the need to change a drug treatment, monthly spending on drugs, and rate of surgery cancellation (p > 0.05) ( Table 2) .

A higher proportion of patients in the DOD group than in the NDOD group reported that they were sadder and had greater difficulty sleeping (p < 0.01). The groups did not differ in terms of overall perceived health, anxiety, stress, depression, or reduced walking capability (p > 0.05) ( Table 2 ).

The main finding of this study was that 17% of the patients reported difficulties obtaining their medications during the pandemic and a greater proportion of these patients reported feeling sadder and having greater difficulty sleeping than those who did not have difficulties obtaining their drugs during the Covid-19 pandemic.

The majority of patients in both groups were elderly, with moderate severity PAD, and had SAH, dyslipidemia, DM, and/or cardiac and musculoskeletal diseases, classifying them as at high risk from COVID-19. 14, 15 In this respect, 87% of the patients in both groups have been following social isolation recommendations. However, although social isolation reduces the risk of COVID-19 contagion, 16, 17 it may also have a negative impact on the drug treatments of some patients with PAD, since they generally collect them in person, for which they need to have up-to-date medical prescriptions, and because many of these patients are dependent on the public healthcare system. In the present study, approximately 17% of the patients reported finding it difficult to obtain their medications during the pandemic. Although we did not observe a difference between the groups in terms of the percentage of patients who stated they were responsible for collecting their own drugs, the patients in the DOD group exhibited a trend to higher monthly spending on medications. In this respect, it could be speculated that these patients' family incomes could have been impacted by the Covid-19 pandemic.

Other factors could also have had an influence on their difficulty obtaining their drugs, such as the regions in which they reside, the regions in which hospitals and health centers are located, and the distance between their places of residence and these services, among other factors. Future studies are needed to investigate this problem. Social isolation has also had negative impacts on the lifestyle of the population, resulting in worse dietary habits, increased inactivity, and deteriorating health and quality of life. [8] [9] [10] [11] 18 This situation may be even more severe among individuals with comorbidities (e.g. patients with psoriasis) with low adherence to drug treatment during the Covid-19 pandemic. 19 In the present study, a higher proportion of patients with PAD in the DOD group reported feeling sadder and having greater difficulty with sleeping compared with those in the NDOD group. This is of concern, because this scenario has been associated with reduced quality of life in these patients. [20] [21] [22] Although there were no differences between the groups in the other health-related parameters, it is important to emphasize that in both groups there was a high prevalence of patients who were more anxious, 9 Patients in both groups also reported deterioration of their capability to walk, which may be related to increased inactivity. Farah et al. 23 reported an association between inactivity and reduced walking capability in patients with PAD.

Moreover, approximately 8% of these patients had cancelled surgery. This finding is of concern, since Li et al. 24 observed that the lower number of patients with PAD who underwent surgery during the Covid-19 pandemic had a higher rate of perioperative complications compared with before the pandemic. These results demonstrate the importance of adoption of strategies to improve accessibility to care provided by health professionals and also to make it easier to obtain medications.

This study is subject to certain limitations. 1) it is a cross-sectional study and so cannot establish cause and effect; 2) self-report assessment was employed, making the study susceptible to information bias; 3) the results cannot be extrapolated to other populations with different characteristics; and 4) neither the percentage of patients dependent on the Brazilian National Health Service (Sistema Único de Saúde) who receive their drugs free of charge nor the possible reasons why patients had difficulty obtaining their drugs were investigated.

A higher proportion of patients in the DOD group than in the NDOD group reported that they felt sadder and had greater difficulty sleeping during the Covid-19 pandemic. 8 

A doença arterial periférica (DAP), cuja prevalência é maior entre os indivíduos idosos, é caracterizada pela presença de lesão estenosante ou obstrutiva nas artérias periféricas, normalmente devido à aterosclerose, levando a uma redução ou oclusão na luz do vaso e do fluxo sanguíneo para os membros, principalmente os inferiores 1 Entre as consequências que a pandemia trouxe para a população destacam-se o aumento do sedentarismo, percepção de piora na capacidade física, na saúde e, consequentemente, a redução da qualidade de vida [8] [9] [10] [11] . O quadro clínico pode ser ainda mais grave nos indivíduos que dependem exclusivamente do sistema público de saúde para o tratamento das doenças, incluindo os pacientes com DAP. De fato, esses pacientes têm enfrentado dificuldades para ter acesso aos seus medicamentos, visto que sua obtenção, geralmente, ocorre de forma presencial e em posse de receitas médicas atualizadas. Dessa forma, o isolamento social tem potencializado a dificuldade no tratamento desses pacientes, que comumente já apresentavam dificuldades de segui-lo corretamente antes da pandemia da COVID-19 12 .

Nesse contexto, o objetivo deste estudo foi analisar o impacto da pandemia da COVID-19 no tratamento medicamentoso dos pacientes com DAP e CI.

Trata-se de um estudo observacional transversal comparativo, que envolveu pacientes com DAP e CI. As informações das características dos pacientes foram obtidas a partir do banco de dados dos estudos desenvolvidos pelo Grupo de Estudo e Pesquisa em Intervenções Clínicas nas Doenças Cardiovasculares (GEPICARDIO). Os dados relativos ao impacto da COVID-19 nos pacientes foram obtidos por meio de entrevista telefônica, entre 15 de maio a 22 de agosto de 2020, por profissionais de saúde com experiência em estudos com pacientes com DAP.

Este estudo foi aprovado pelo Comitê de Ética da Universidade Nove de Julho (CAAE nº 31529220.8.0000.5511; número do parecer: 4.023.509). As respostas dos participantes só foram incluídas após o consentimento dos mesmos. Todos os procedimentos seguiram a legislação nacional e a Declaração de Helsinque.

Os pacientes foram incluídos se atendessem aos seguintes critérios: a) diagnóstico de DAP; b) idade ≥ 45 anos; c) valor prévio do índice tornozelo-braquial ≤ 0,90; d) diagnóstico prévio com estágio II da classificação de Fontaine; e) ausência de vasos não compressíveis, membros amputados e/ou úlceras. Os pacientes só foram excluídos se: a) apresentassem algum comprometimento durante a ligação telefônica, que pudesse comprometer a aplicação do questionário (e.g. cognitivo, auditivo e de fala).

As informações pessoais foram acessadas no nosso banco de dados: sexo ("mulher" ou "homem"), data de nascimento (DD/MM/AAAA), tempo de diagnóstico de DAP (em anos), índice de massa corporal (kg/m 2 ) e a severidade da DAP (Índice tornozelo-braquial e estágio de Fontaine) 3, 13 . O questionário aplicado é extenso, mas para os objetivos deste estudo foram utilizadas apenas as questões específicas descritas abaixo:

Tabagismo: 1-Você fuma?; 2-Você é ex-fumante? As respostas possíveis para todos os itens foram: "Não" ou "Sim".

Doenças associadas: a partir de uma lista de doenças, o participante informou todas as doenças diagnosticadas (i.e. respostas possíveis: DM, HAS, dislipidemias, doença cardíaca, respiratória, osteomuscular ou outros). As respostas possíveis para todos os itens foram: "Não" ou "Sim".

COVID-19: 1-Você está em isolamento social?; 2-Você foi diagnosticado com COVID-19?; Se sim, 3-Você já está recuperado? As respostas possíveis para todos os itens foram: "Não" ou "Sim".

Tratamento da doença: 1-Teve dificuldade para adquirir os seus medicamentos nos últimos meses devido à COVID-19?; 2-Precisou mudar o tipo/dose de algum medicamento?; 3-O senhor é responsável por buscar os seus medicamentos?; 4-Qual o gasto mensal com medicamentos?; 5-Precisou cancelar alguma cirurgia? As respostas possíveis para os itens 1, 2, 3 e 5 foram: "Não" ou "Sim". Para o item 4, foram: "Até R$ 100,00" ou "R$ 101 a 200,00" ou "R$ 201 a 400,00" ou "Mais de R$ 401,00".

Saúde global: 1-Como está a sua saúde durante a pandemia da COVID-19? (respostas possíveis: "Boa/igual" ou "Ruim"); 2-Tem sentido dificuldade para dormir?; 3-Devido à COVID-19, você está se sentindo mais ansioso?; 4-Devido à COVID-19, você está se sentindo mais triste?; 5-Devido à COVID-19, você está se sentindo mais estressado? 6-Devido à COVID-19, você está se sentindo deprimido?; 7-Você sentiu que a sua capacidade de caminhada diminuiu nas últimas semanas? As respostas possíveis para as questões 2 a 7 foram: "Não" ou "Sim".

Ao final das entrevistas, os pacientes foram divididos em dois grupos, de acordo com a dificuldade para a aquisição do medicamento (DAM: dificuldade para adquirir o medicamento e SDAM: sem dificuldade para adquirir o medicamento).

Todas as análises foram realizadas pelo software Statistical Package for the Social Sciences ® (SPSS, versão 20). A comparação entre os pacientes que tiveram e os que não tiveram dificuldades para adquirir os medicamentos foi realizada através do teste t independente ou teste U de Mann-Whitney e o teste de qui-quadrado. Os dados estão apresentados como média e desvio padrão para as variáveis contínuas e frequência relativa para as variáveis categóricas. A significância foi definida com p < 0,05.

Os 136 pacientes com DAP e CI que responderam ao questionário foram divididos em dois grupos, de acordo com a dificuldade para a aquisição dos medicamentos (SDAM: 113 pacientes e DAM: 23 pacientes). Os grupos apresentaram semelhantes características físicas, fatores de risco e doenças associadas e porcentagem de pessoas seguindo o isolamento social (p > 0,05) (Tabela 1).

Os grupos também apresentaram resultados similares em relação à porcentagem de pacientes responsáveis por buscarem os próprios medicamentos, necessidade de mudança no tratamento medicamentoso, gasto mensal com os mesmos e taxa de cancelamento das cirurgias (p > 0,05) (Tabela 2).

Uma maior prevalência de pacientes do grupo DAM reportou estar mais triste e com mais dificuldades para dormir em relação aos pacientes do grupo SDAM (p < 0,01). Os grupos não apresentaram diferenças para a percepção da saúde geral, ansiedade, estresse, depressão e declínio na capacidade de caminhada (p > 0,05) (Tabela 2).

O principal achado do presente estudo foi que 17% dos pacientes reportaram dificuldades para a aquisição dos medicamentos durante a pandemia e uma maior prevalência desses pacientes reportou estar mais triste e com mais dificuldade para dormir em comparação ao grupo SADM durante a pandemia da COVID-19. A maioria dos pacientes de ambos os grupos é de idosos, com moderada severidade da DAP e apresentam HAS, dislipidemias, DM e doenças cardíacas e osteomusculares, o que os classifica como grupo de risco para a COVID-19 14, 15 . Nesse contexto, 87% dos pacientes de ambos os grupos têm seguido as recomendações para o isolamento social.

No entanto, apesar do menor risco de contágio da COVID-19 com a adoção do isolamento social 16, 17 , isso também pode estar impactando negativamente no tratamento medicamentoso de alguns pacientes com DAP, visto que a sua obtenção geralmente ocorre de forma presencial e em posse de receitas médicas atualizadas, sendo que muitos pacientes são dependentes do sistema público de saúde. No presente estudo, aproximadamente 17% dos pacientes reportaram dificuldades para a aquisição dos medicamentos durante a pandemia. Embora não tenhamos observado diferenças entre os grupos na porcentagem de pacientes que reportaram ser responsáveis por buscar o próprio medicamento, os pacientes do grupo DAM apresentaram uma tendência a ter um maior gasto mensal com os medicamentos. Nesse contexto, é possível especular que a renda familiar desses pacientes tenha sido afetada durante a pandemia da COVID-19. Outros fatores também podem ter influenciado na dificuldade da aquisição dos mesmos, como a região onde se encontram os hospitais e os postos de saúde, a distância da residência e esses lugares, entre outros. Futuros estudos são necessários para investigar essa problemática.

O isolamento social também tem impactado negativamente no estilo de vida da população, resultando em um pior hábito alimentar, aumento do sedentarismo e piora da saúde e da qualidade de vida [8] [9] [10] [11] 18 . Esse quadro pode ser ainda mais grave entre os indivíduos portadores de comorbidades (e.g. pacientes com psoríase) com baixa aderência ao tratamento medicamentoso durante a pandemia da COVID-19 19 prevalência dos pacientes com DAP do grupo DAM reportaram estar mais triste e com mais dificuldade para dormir em comparação ao grupo SDAM. Isso é preocupante, pois esse quadro tem sido associado à uma redução na qualidade de vida desses pacientes [20] [21] [22] . Embora os outros parâmetros relacionados à saúde não tenham apresentado diferenças entre os grupos, é importante destacar que uma alta prevalência dos pacientes em ambos os grupos está mais ansiosa, estressada e deprimida durante a pandemia da COVID-19. Esse resultado está de acordo com o observado em indivíduos sem a DAP 9 . Os pacientes de ambos os grupos também reportaram prejuízo na capacidade de caminhada, o que pode estar relacionado com o aumento do sedentarismo. Farah et al. 23 reportaram associação entre sedentarismo e a pior capacidade de caminhada em pacientes com DAP.

Ademais, aproximadamente 8% desses pacientes cancelaram as cirurgias. O quadro é preocupante, uma vez que Li et al. 24 observaram que o número reduzido de pacientes com DAP submetidos a cirurgias durante a pandemia da COVID-19 apresentavam uma maior taxa de complicações perioperatórias comparada aos de antes da pandemia. Esses resultados demonstram a importância da adoção de estratégias que tornem mais acessíveis os atendimentos com os diferentes profissionais da área da saúde, assim como uma maior facilidade na aquisição dos medicamentos.

Este estudo possui algumas limitações. 1) é um estudo transversal e não permite estabelecer causa e efeito; 2) foi utilizada uma avaliação autorreferida, o que torna suscetível o viés de informação; 3) os resultados não podem ser extrapolados para outras populações com outras características; 4) não foi avaliada a porcentagem de pacientes dependentes do Sistema Único de Saúde e que recebem gratuitamente os medicamentos para o tratamento da DAP, assim como os possíveis motivos referentes à dificuldade para a obtenção dos mesmos.

Uma maior prevalência de pacientes do grupo DAM reportou estar mais triste e com mais dificuldade para dormir em comparação ao grupo SDAM durante a pandemia da COVID-19.

Peripheral arterial disease: Pathophysiology, risk factors, diagnosis, treatment, and prevention

Predictive value of the ankle-brachial index in the evaluation of intermittent claudication

Predictors of walking capacity in peripheral arterial disease patients

Intermittent claudication in older patients: risk factors, cardiovascular comorbidity, and severity of peripheral arterial disease

Impact of claudication and its treatment on quality of life

Coronavirus disease (COVID-19) pandemic

Peripheral arterial disease: Pathophysiology, risk factors, diagnosis, treatment, and prevention

Predictive value of the ankle-brachial index in the evaluation of intermittent claudication

Predictors of walking capacity in peripheral arterial disease patients

Intermittent claudication in older patients: risk factors, cardiovascular comorbidity, and severity of peripheral arterial disease

Impact of claudication and its treatment on quality of life

Coronavirus disease (COVID-19) pandemic

Social isolation during the COVID-19 pandemic can increase physical inactivity and the global burden of cardiovascular disease

The same storm but not same the boat: Effects of COVID-19 stay-at-home order on mental health in individuals with overweight

Reduction of physical activity levels during the COVID-19 pandemic might negatively disturb sleep patern

Health-related quality of life and resilience in peri-and postmenopausal women during Covid-19 confinement

Adherence to statin therapy favours survival of patients with symptomatic peripheral artery disease

Measurement and interpretation of the ankle-brachial index: a scientific statement from the American Heart Association

Risk factors associated with worse outcomes in COVID-19: a retrospective study in Saudi Arabia

Adults at high-risk of severe coronavirus disease-2019 (Covid-19) in Brazil

The timing and intensity of social distancing to flatten the COVID-19 Curve: the case of Spain

The effect of large-scale anti-contagion policies on the COVID-19 pandemic

Eating in the lockdown the Covid 19 pandemic; self-reported changes in eating behaviour, and associations with BMI, eating style, coping and health anxiety

Nonadherence to treatment and patientreported outcomes of psoriasis during the COVID-19 epidemic: a web-based survey

Translation and Validation of the Brazilian-Portuguese Short Version of Vascular Quality of Life Questionnaire in Peripheral Artery Disease Patients with Intermittent Claudication Symptoms

Health-related quality of life among patients with peripheral arterial disease

The connection between obstructive sleep apnea and peripheral artery disease

Factors associated with sedentary behavior in patients with intermittent claudication

Impact of COVID-19 on peripheral arterial disease treatment

Programa de Pósgraduação em Ciências da Reabilitação Rua Vergueiro, 235 CEP 01504-000 -São Paulo (SP)

raphaelritti@gmail.com Informações sobre os autores HAB e PL -Estudantes, Programa de Pós-graduação em Ciências da Reabilitação

Programa de Pós-graduação em Ciências da Saúde

Programa de Pós-graduação em Ciências da Reabilitação

Contribuições dos autores Concepção e desenho

*Todos os autores leram e aprovaram a versão final submetida ao J Vasc Bras